Ophthalmology biotechnology company Tarsier Pharma (TARX.US) applies to go public in the United States, aiming to raise $35 million.

Focused on clinical-stage biotechnology company specializing in ophthalmic diseases, Tarsier Pharma submitted a filing with the U.S. Securities and Exchange Commission (SEC) on Tuesday, planning to raise up to $35 million through an initial public offering (IPO). The company plans to list on the NYSE's small and mid-cap market under the ticker symbol "TARX". Founded in 2016, Tarsier Pharma is dedicated to developing novel therapies for inflammatory eye diseases that can lead to blindness. Its lead platform is based on the immuno-modulating compound dazdotuftide, aimed at treating diseases like non-infectious anterior uveitis without relying on steroids - which, while currently the standard therapy, may increase the risk of glaucoma. The company is advancing two formulations, eye drops (TRS01) and injectables (TRS02), to reduce inflammation while avoiding steroid-related side effects, targeting the large unmet medical needs in the uveitis and glaucoma patient population.